- Home
- ACAD vs VVV Comparison
ACAD vs VVV Comparison
Compare ACAD & VVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- VVV
- Stock Information
- Founded
- ACAD 1993
- VVV 1866
- Country
- ACAD United States
- VVV United States
- Employees
- ACAD N/A
- VVV N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- VVV Major Chemicals
- Sector
- ACAD Health Care
- VVV Industrials
- Exchange
- ACAD Nasdaq
- VVV Nasdaq
- Market Cap
- ACAD 4.0B
- VVV 5.0B
- IPO Year
- ACAD 2004
- VVV 2016
- Fundamental
- Price
- ACAD $25.99
- VVV $38.76
- Analyst Decision
- ACAD Buy
- VVV Buy
- Analyst Count
- ACAD 20
- VVV 12
- Target Price
- ACAD $28.63
- VVV $42.50
- AVG Volume (30 Days)
- ACAD 2.0M
- VVV 1.7M
- Earning Date
- ACAD 08-06-2025
- VVV 08-06-2025
- Dividend Yield
- ACAD N/A
- VVV N/A
- EPS Growth
- ACAD 615.00
- VVV 68.45
- EPS
- ACAD 1.33
- VVV 2.14
- Revenue
- ACAD $1,018,885,000.00
- VVV $1,692,000,000.00
- Revenue This Year
- ACAD $14.01
- VVV $6.86
- Revenue Next Year
- ACAD $11.72
- VVV $14.28
- P/E Ratio
- ACAD $19.61
- VVV $18.09
- Revenue Growth
- ACAD 14.41
- VVV 7.53
- 52 Week Low
- ACAD $13.40
- VVV $31.02
- 52 Week High
- ACAD $26.65
- VVV $43.74
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- VVV 52.84
- Support Level
- ACAD $25.14
- VVV $39.03
- Resistance Level
- ACAD $26.65
- VVV $39.79
- Average True Range (ATR)
- ACAD 0.67
- VVV 0.76
- MACD
- ACAD 0.04
- VVV -0.05
- Stochastic Oscillator
- ACAD 70.27
- VVV 24.51
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.